Genmab A/S - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
GMAB Nasdaq 2830 www.genmab.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Genmab A/S

Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival - Jun 29th, 2026 2:15 pm
VERAXA Unveils Cancer Therapy Platform, Sparks Partnering Talks at BIO 2026 - Jun 18th, 2026 8:34 am
Capital Increase in Genmab as a Result of Employee Warrant Exercise - Jun 16th, 2026 1:12 pm
Major Shareholder Announcement - Jun 15th, 2026 10:04 am
Genmab’s EPCORE Data Deepens Lymphoma Profile As Investors Weigh Upside - Jun 15th, 2026 4:07 am
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) - Jun 13th, 2026 10:45 am
Grant of Restricted Stock Units and Warrants to Employees in Genmab - Jun 11th, 2026 11:17 am
Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients - Jun 11th, 2026 8:45 am
Truist Assigns Buy Rating to Genmab (GMAB) - Jun 5th, 2026 10:36 am
Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons - May 29th, 2026 2:35 pm
Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress - May 21st, 2026 3:00 pm
Genmab (CPSE:GMAB) Valuation Check After Recent Share Price Softness And 24.6% Undervaluation Estimate - May 16th, 2026 6:19 pm
Morgan Stanley Maintains an “Equal Weight” Rating on Genmab A/S (GMAB) - May 13th, 2026 11:53 am
Is It Time To Reassess Genmab (CPSE:GMAB) After Mixed Multi‑Year Share Performance - May 8th, 2026 6:17 am
Genmab A/S Q1 Earnings Call Highlights - May 7th, 2026 2:58 pm
DARZALEX royalties drive Genmab’s Q1 revenue higher amid expansion push - May 7th, 2026 12:46 pm
Genmab Announces Financial Results for the First Quarter of 2026 - May 7th, 2026 9:02 am
Genmab (GMAB) Rated Outperform on Oncology Pipeline - May 2nd, 2026 11:51 am
Genmab A/S (GMAB) Rating Lifted by Goldman Sachs on Strong 2026 Catalyst Outlook - Apr 24th, 2026 7:42 am
BioNTech (BNTX) Surges 6.1%: Is This an Indication of Further Gains? - Apr 22nd, 2026 8:10 am